A 58-year-old postmenopausal woman from Delhi presents with abnormal uterine bleeding. Endometrial biopsy shows a Grade 1 adenocarcinoma with myometrial invasion to the inner third. Immunohistochemistry shows PTEN loss, KRAS mutation, and intact p53. Which feature best distinguishes this tumor from a serous variant and predicts a more favorable prognosis?

Explanation

## Type 1 vs Type 2 Endometrial Carcinoma: Key Discriminators ### Clinical Context and Diagnosis This patient presents with a **Grade 1 endometrioid adenocarcinoma** with intact p53, PTEN loss, and KRAS mutation — the classic molecular and histological profile of **Type 1 (endometrioid) endometrial carcinoma**. The question asks which single feature **best distinguishes** this tumor from serous (Type 2) carcinoma and predicts favorable prognosis. ### Comparative Features: Type 1 vs Type 2 | Feature | Type 1 (Endometrioid) | Type 2 (Serous) | |---|---|---| | **Grade** | 1–2 (low) | 3 (high) | | **p53 status** | Wild-type/intact (>90%) | Mutated/aberrant (>80%) | | **PTEN/KRAS/PIK3CA** | Frequently altered | Rare | | **Architecture** | Glandular ± squamous metaplasia | Papillary, micropapillary | | **ER/PR** | Positive | Negative/reduced | | **Myometrial invasion** | Superficial | Often deep | | **5-Year OS (Stage I)** | ~85% | ~50% | ### Why Option A is Correct **Intact p53 expression combined with low-grade histology** is the single most reliable and clinically validated discriminator between Type 1 and Type 2 endometrial carcinoma: - **Serous carcinoma (Type 2)** is defined by **aberrant/mutant p53** in >80% of cases — this is its molecular hallmark per the 2020 WHO/TCGA classification. - **Intact (wild-type) p53** directly excludes the serous subtype and, together with Grade 1 histology, is the most specific combination for predicting indolent behavior and favorable prognosis. - This pairing is used in routine IHC panels to distinguish endometrioid from serous carcinoma. ### Why the Other Options Are Incorrect - **Option B:** PTEN loss and KRAS mutations are part of the **PI3K/AKT pathway**, NOT the POLE pathway. POLE mutations define a separate, ultra-mutated molecular subtype (TCGA). This option contains a factual error and is therefore incorrect. - **Option C:** Limited myometrial invasion and ER positivity are supportive features but are neither specific nor sufficient alone to exclude serous carcinoma, which can occasionally be ER-positive or superficially invasive. - **Option D:** Glandular architecture with squamous metaplasia and PTEN/KRAS alterations are characteristic of Type 1, but squamous metaplasia is a histological finding that is not routinely used as a primary discriminator in IHC-based classification. Intact p53 remains the gold-standard IHC marker for this distinction. ### Key Point **High-Yield:** Per Robbins Pathology (10e, Ch. 24) and the TCGA molecular classification, **aberrant p53 is the defining molecular hallmark of serous (Type 2) endometrial carcinoma**. Therefore, **intact p53 + low-grade histology** is the best single combination to distinguish Type 1 from Type 2 and predict favorable prognosis. ### Clinical Pearl **Tip:** In NEET PG/INI-CET, when a question asks what distinguishes endometrioid from serous endometrial carcinoma, the answer pivots on **p53 status**. Serous = mutant p53; Endometrioid = intact p53. PTEN/KRAS mutations support Type 1 but are not the primary discriminator from Type 2. [cite: Robbins & Cotran Pathologic Basis of Disease, 10e, Ch. 24; TCGA Research Network, Nature 2013]